60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a report issued on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 28th.

60 Degrees Pharmaceuticals Price Performance

60 Degrees Pharmaceuticals stock opened at $3.10 on Tuesday. The firm has a market cap of $4.57 million, a PE ratio of -0.31 and a beta of 3.41. The stock’s fifty day moving average price is $2.19 and its two-hundred day moving average price is $4.29. 60 Degrees Pharmaceuticals has a one year low of $1.41 and a one year high of $35.99.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.